{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:40:14Z","timestamp":1770824414983,"version":"3.50.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T00:00:00Z","timestamp":1629158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T00:00:00Z","timestamp":1629158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neth Heart J"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients with coronary disease remain at high risk for future cardiovascular events, even with optimal risk factor modification, lipid-lowering drugs and  antithrombotic regimens. A\u00a0myriad of inflammatory pathways contribute to progression of the atherosclerotic burden in these patients. Only in the last few years has the inflammatory biology of atherosclerosis translated into clinical therapeutic options. Low-dose colchicine can provide a\u00a0clinically relevant reduction in the risk for composite and individual major cardiovascular outcomes in patients with acute and chronic coronary syndromes. Among others, its anti-inflammatory effects in atherosclerosis seem to be related to neutrophil recruitment and adhesion, inflammasome inhibition, and morphological changes in platelets and platelet aggregation. Future research is aimed at further elucidating its particular mechanism of action, as well as identifying patients with the highest expected benefit and evaluating efficacy in other vascular beds. These data will help to formulate the role of colchicine and other anti-inflammatory drugs in patients with coronary disease and atherosclerosis in general in the near future.<\/jats:p>","DOI":"10.1007\/s12471-021-01605-3","type":"journal-article","created":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T11:03:08Z","timestamp":1629198188000},"page":"25-37","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Targeting residual inflammatory risk in coronary disease: to catch a\u00a0monkey by its tail"],"prefix":"10.1007","volume":"30","author":[{"given":"A. T. L.","family":"Fiolet","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. S. J.","family":"Opstal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. J. M.","family":"Silvis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. H.","family":"Cornel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6906-2643","authenticated-orcid":false,"given":"A.","family":"Mosterd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,17]]},"reference":[{"key":"1605_CR1","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1161\/CIRCULATIONAHA.114.008720","volume":"132","author":"GA Roth","year":"2015","unstructured":"Roth\u00a0GA, Huffman\u00a0MD, Moran\u00a0AE, et\u00a0al. Global and regional patterns in cardiovascular mortality from 1990 to 2013. Circulation. 2015;132:1667\u201378.","journal-title":"Circulation"},{"key":"1605_CR2","doi-asserted-by":"publisher","first-page":"m2688","DOI":"10.1136\/bmj.m2688","volume":"370","author":"NS Shah","year":"2020","unstructured":"Shah\u00a0NS, Molsberry\u00a0R, Rana\u00a0JS, et\u00a0al. Heterogeneous trends in burden of heart disease mortality by subtypes in the United States, 1999\u20132018: observational analysis of vital statistics. BMJ. 2020;370:m2688.","journal-title":"BMJ"},{"key":"1605_CR3","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/nrcardio.2015.82","volume":"12","author":"M Ezzati","year":"2015","unstructured":"Ezzati\u00a0M, Obermeyer\u00a0Z, Tzoulaki\u00a0I, Mayosi\u00a0BM, Elliott\u00a0P, Leon\u00a0DA. Contributions of risk factors and medical care to cardiovascular mortality trends. Nat Rev Cardiol. 2015;12:508\u201330.","journal-title":"Nat Rev Cardiol"},{"key":"1605_CR4","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration","year":"2010","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a\u00a0meta-analysis of data from 170 000\u00a0participants in 26 randomised trials. Lancet. 2010;376:1670\u201381.","journal-title":"Lancet"},{"key":"1605_CR5","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1136\/bmj.326.7380.84","volume":"326","author":"P Murchie","year":"2003","unstructured":"Murchie\u00a0P, Campbell\u00a0NC, Ritchie\u00a0LD, Simpson\u00a0JA, Thain\u00a0J. Secondary prevention clinics for coronary heart disease: four year follow up of a\u00a0randomised controlled trial in primary care. BMJ. 2003;326:84.","journal-title":"BMJ"},{"key":"1605_CR6","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz\u00a0GG, Steg\u00a0PG, Szarek\u00a0M, et\u00a0al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N\u00a0Engl J Med. 2018;379:2097\u2013107.","journal-title":"N Engl J Med"},{"key":"1605_CR7","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1161\/CIRCRESAHA.116.310527","volume":"120","author":"PM Ridker","year":"2017","unstructured":"Ridker\u00a0PM. How common is residual inflammatory risk? Circ Res. 2017;120:617\u20139.","journal-title":"Circ Res"},{"key":"1605_CR8","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine\u00a0MS, Giugliano\u00a0RP, Keech\u00a0AC, et\u00a0al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N\u00a0Engl J Med. 2017;376:1713\u201322.","journal-title":"N Engl J Med"},{"key":"1605_CR9","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/eurheartj\/ehaa099","volume":"42","author":"PR Lawler","year":"2021","unstructured":"Lawler\u00a0PR, Bhatt\u00a0DL, Godoy\u00a0LC, et\u00a0al. Targeting cardiovascular inflammation: next steps in clinical translation. Eur Heart\u00a0J. 2021;42:113\u201331.","journal-title":"Eur Heart J"},{"key":"1605_CR10","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S0140-6736(09)61717-7","volume":"375","author":"Emerging Risk Factors Collaboration","year":"2010","unstructured":"Emerging Risk Factors Collaboration. C\u2011reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375:132\u201340.","journal-title":"Lancet"},{"key":"1605_CR11","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa042378","volume":"352","author":"PM Ridker","year":"2005","unstructured":"Ridker\u00a0PM, Cannon\u00a0CP, Morrow\u00a0D, et al. C\u2011reactive protein levels and outcomes after statin therapy. N\u00a0Engl J Med. 2005;352:20\u20138.","journal-title":"N Engl J Med"},{"key":"1605_CR12","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon\u00a0CP, Blazing\u00a0MA, Giugliano\u00a0RP, et\u00a0al. Ezetimibe added to statin therapy after acute coronary syndromes. N\u00a0Engl J Med. 2015;372:2387\u201397.","journal-title":"N Engl J Med"},{"key":"1605_CR13","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/S0140-6736(09)60447-5","volume":"373","author":"PM Ridker","year":"2009","unstructured":"Ridker\u00a0PM, Danielson\u00a0E, Fonseca\u00a0FAH, et al. Reduction in C\u2011reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a\u00a0prospective study of the JUPITER trial. Lancet. 2009;373:1175\u201382.","journal-title":"Lancet"},{"key":"1605_CR14","doi-asserted-by":"publisher","first-page":"d548","DOI":"10.1136\/bmj.d548","volume":"342","author":"C Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC)","year":"2011","unstructured":"C Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC). Association between C reactive protein and coronary heart disease: mendelian randomisation analysis based on individual participant data. BMJ. 2011;342:d548.","journal-title":"BMJ"},{"key":"1605_CR15","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/S0140-6736(12)60110-X","volume":"379","author":"Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium","year":"2012","unstructured":"Interleukin\u20116 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium. The interleukin\u20116 receptor as a\u00a0target for prevention of coronary heart disease: a\u00a0mendelian randomisation analysis. Lancet. 2012;379:1214\u201324.","journal-title":"Lancet"},{"key":"1605_CR16","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker\u00a0PM, Everett\u00a0BM, Thuren\u00a0T, et\u00a0al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N\u00a0Engl J Med. 2017;377:1119\u201331.","journal-title":"N Engl J Med"},{"key":"1605_CR17","doi-asserted-by":"publisher","first-page":"j1909","DOI":"10.1136\/bmj.j1909","volume":"357","author":"M Bally","year":"2017","unstructured":"Bally\u00a0M, Dendukuri\u00a0N, Rich\u00a0B, et al. Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ. 2017;357:j1909.","journal-title":"BMJ"},{"key":"1605_CR18","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1056\/NEJMra052717","volume":"353","author":"C Patrono","year":"2005","unstructured":"Patrono\u00a0C, Garc\u00eda Rodr\u00edguez\u00a0LA, Landolfi\u00a0R, Baigent\u00a0C. Low-dose aspirin for the prevention of atherothrombosis. N\u00a0Engl J Med. 2005;353:2373\u201383.","journal-title":"N Engl J Med"},{"key":"1605_CR19","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/nrd1929","volume":"5","author":"JA Mitchell","year":"2006","unstructured":"Mitchell\u00a0JA, Warner\u00a0TD. COX isoforms in the cardiovascular system: understanding the activities of non-steroidal anti-inflammatory drugs. Nat Rev Drug Discov. 2006;5:75\u201386.","journal-title":"Nat Rev Drug Discov"},{"key":"1605_CR20","doi-asserted-by":"publisher","first-page":"764","DOI":"10.7326\/0003-4819-141-10-200411160-00007","volume":"141","author":"L Wei","year":"2004","unstructured":"Wei\u00a0L, MacDonald\u00a0TM, Walker\u00a0BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med. 2004;141:764\u201370.","journal-title":"Ann Intern Med"},{"key":"1605_CR21","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1056\/NEJMoa1315878","volume":"370","author":"HD White","year":"2014","unstructured":"White\u00a0HD, Held\u00a0C, Stewart\u00a0R, et\u00a0al. Darapladib for preventing ischemic events in stable coronary heart disease. N\u00a0Engl J Med. 2014;370:1702\u201311.","journal-title":"N Engl J Med"},{"key":"1605_CR22","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1001\/jama.2014.11061","volume":"312","author":"ML O\u2019Donoghue","year":"2014","unstructured":"O\u2019Donoghue\u00a0ML, Braunwald\u00a0E, White\u00a0HD, et al. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA. 2014;312:1006\u201315.","journal-title":"JAMA"},{"key":"1605_CR23","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1001\/jama.2013.282836","volume":"311","author":"SJ Nicholls","year":"2014","unstructured":"Nicholls\u00a0SJ, Kastelein\u00a0JJP, Schwartz\u00a0GG, et al. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. JAMA. 2014;311:252\u201362.","journal-title":"JAMA"},{"key":"1605_CR24","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1001\/jama.2016.3609","volume":"315","author":"ML O\u2019Donoghue","year":"2016","unstructured":"O\u2019Donoghue\u00a0ML, Glaser\u00a0R, Cavender\u00a0MA, et\u00a0al. Effect of losmapimod on cardiovascular outcomes in patients hospitalized with acute myocardial infarction: a\u00a0randomized clinical trial. JAMA. 2016;315:1591\u20139.","journal-title":"JAMA"},{"key":"1605_CR25","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1056\/NEJMoa1809798","volume":"380","author":"PM Ridker","year":"2018","unstructured":"Ridker\u00a0PM, Everett\u00a0BM, Pradhan\u00a0A, et al. Low-dose methotrexate for the prevention of atherosclerotic events. N\u00a0Engl J Med. 2018;380:752\u201362.","journal-title":"N Engl J Med"},{"key":"1605_CR26","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","volume":"381","author":"J-C Tardif","year":"2019","unstructured":"Tardif\u00a0J\u2011C, Kouz\u00a0S, Waters\u00a0DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N\u00a0Engl J Med. 2019;381:2497\u2013505.","journal-title":"N Engl J Med"},{"key":"1605_CR27","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","volume":"383","author":"SM Nidorf","year":"2020","unstructured":"Nidorf\u00a0SM, Fiolet\u00a0ATL, Mosterd\u00a0A, et\u00a0al. Colchicine in patients with chronic coronary disease. N\u00a0Engl J Med. 2020;383:1838\u201347.","journal-title":"N Engl J Med"},{"key":"1605_CR28","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.semarthrit.2015.06.013","volume":"45","author":"YY Leung","year":"2015","unstructured":"Leung\u00a0YY, Hui\u00a0LLY, Kraus\u00a0VB. Colchicine\u2014update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum. 2015;45:341\u201350.","journal-title":"Semin Arthritis Rheum"},{"key":"1605_CR29","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1161\/CIRCULATIONAHA.105.542738","volume":"112","author":"M Imazio","year":"2005","unstructured":"Imazio\u00a0M, Bobbio\u00a0M, Cecchi\u00a0E, et\u00a0al. Colchicine in addition to conventional therapy for acute pericarditis: results of the COlchicine for acute PEricarditis (COPE) trial. Circulation. 2005;112:2012\u20136.","journal-title":"Circulation"},{"key":"1605_CR30","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1056\/NEJMoa1208536","volume":"369","author":"M Imazio","year":"2013","unstructured":"Imazio\u00a0M, Brucato\u00a0A, Cemin\u00a0R, et\u00a0al. A randomized trial of colchicine for acute pericarditis. N\u00a0Engl J Med. 2013;369:1522\u20138.","journal-title":"N Engl J Med"},{"key":"1605_CR31","doi-asserted-by":"publisher","first-page":"e0237665","DOI":"10.1371\/journal.pone.0237665","volume":"15","author":"ATL Fiolet","year":"2020","unstructured":"Fiolet\u00a0ATL, Silvis\u00a0MJM, Opstal\u00a0TSJ, et al. Short-term effect of low-dose colchicine on inflammatory biomarkers, lipids, blood count and renal function in chronic coronary artery disease and elevated high-sensitivity C\u2011reactive protein. PLoS ONE. 2020;15:e237665.","journal-title":"PLoS ONE"},{"key":"1605_CR32","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1161\/CIRCULATIONAHA.120.050560","volume":"142","author":"TSJ Opstal","year":"2020","unstructured":"Opstal\u00a0TSJ, Hoogeveen\u00a0RM, Fiolet\u00a0ATL, et\u00a0al. Colchicine attenuates inflammation beyond the inflammasome in chronic coronary artery disease: a\u00a0LoDoCo2 proteomic substudy. Circulation. 2020;142:1996\u20138.","journal-title":"Circulation"},{"key":"1605_CR33","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1056\/NEJMra2000317","volume":"383","author":"R Vergallo","year":"2020","unstructured":"Vergallo\u00a0R, Crea\u00a0F. Atherosclerotic plaque healing. N\u00a0Engl J Med. 2020;383:846\u201357.","journal-title":"N Engl J Med"},{"key":"1605_CR34","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S0306-9877(98)90031-7","volume":"51","author":"E Ben-Chetrit","year":"1998","unstructured":"Ben-Chetrit\u00a0E, Levy\u00a0M. Does the lack of the P\u2011glycoprotein efflux pump in neutrophils explain the efficacy of colchicine in familial Mediterranean fever and other inflammatory diseases? Med Hypotheses. 1998;51:377\u201380.","journal-title":"Med Hypotheses"},{"key":"1605_CR35","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1189\/jlb.1012510","volume":"94","author":"S Paschke","year":"2013","unstructured":"Paschke\u00a0S, Weidner\u00a0AF, Paust\u00a0T, Marti\u00a0O, Beil\u00a0M, Ben-Chetrit\u00a0E. Technical advance: inhibition of neutrophil chemotaxis by colchicine is modulated through viscoelastic properties of subcellular compartments. J\u00a0Leukoc Biol. 2013;94:1091\u20136.","journal-title":"J Leukoc Biol"},{"key":"1605_CR36","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1172\/JCI118147","volume":"96","author":"BN Cronstein","year":"1995","unstructured":"Cronstein\u00a0BN, Molad\u00a0Y, Reibman\u00a0J, Balakhane\u00a0E, Levin\u00a0RI, Weissmann\u00a0G. Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J\u00a0Clin Invest. 1995;96:994\u20131002.","journal-title":"J Clin Invest"},{"key":"1605_CR37","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.jcmg.2017.08.013","volume":"11","author":"K Vaidya","year":"2018","unstructured":"Vaidya\u00a0K, Arnott\u00a0C, Mart\u00ednez\u00a0GJ, et\u00a0al. Colchicine therapy and plaque stabilization in patients with acute coronary syndrome: a\u00a0CT coronary angiography study. JACC Cardiovasc Imaging. 2018;11:305\u201316.","journal-title":"JACC Cardiovasc Imaging"},{"key":"1605_CR38","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nature04516","volume":"440","author":"F Martinon","year":"2006","unstructured":"Martinon\u00a0F, P\u00e9trilli\u00a0V, Mayor\u00a0A, Tardivel\u00a0A, Tschopp\u00a0J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440:237\u201341.","journal-title":"Nature"},{"key":"1605_CR39","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1182\/blood-2010-07-273417","volume":"117","author":"CA Dinarello","year":"2011","unstructured":"Dinarello\u00a0CA. Interleukin\u20111 in the pathogenesis and treatment of inflammatory diseases. Blood. 2011;117:3720\u201332.","journal-title":"Blood"},{"key":"1605_CR40","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/nature08938","volume":"464","author":"P Duewell","year":"2010","unstructured":"Duewell\u00a0P, Kono\u00a0H, Rayner\u00a0KJ, et\u00a0al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464:1357\u201361.","journal-title":"Nature"},{"key":"1605_CR41","first-page":"467","volume":"54","author":"JG White","year":"1969","unstructured":"White\u00a0JG. Effects of colchicine and vinca alkaloids on human platelets. 3. Influence on primary internal contraction and secondary aggregation. Am J Pathol. 1969;54:467\u201378.","journal-title":"Am J Pathol"},{"key":"1605_CR42","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1007\/s11239-020-02121-8","volume":"50","author":"P Cirillo","year":"2020","unstructured":"Cirillo\u00a0P, Taglialatela\u00a0V, Pellegrino\u00a0G, et\u00a0al. Effects of colchicine on platelet aggregation in patients on dual antiplatelet therapy with aspirin and clopidogrel. J\u00a0Thromb Thrombolysis. 2020;50:468\u201372.","journal-title":"J Thromb Thrombolysis"},{"key":"1605_CR43","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s10753-015-0237-7","volume":"39","author":"B Shah","year":"2016","unstructured":"Shah\u00a0B, Allen\u00a0N, Harchandani\u00a0B, et al. Effect of colchicine on platelet-platelet and platelet-leukocyte interactions: a\u00a0pilot study in healthy subjects. Inflammation. 2016;39:182\u20139.","journal-title":"Inflammation"},{"key":"1605_CR44","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1093\/eurheartj\/ehab115","volume":"45","author":"ATL Fiolet","year":"2021","unstructured":"Fiolet\u00a0ATL, Opstal\u00a0TSJ, Mosterd\u00a0A, et al. Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials. Eur Heart\u00a0J. 2021;45:2765\u201375.","journal-title":"Eur Heart\u00a0J."},{"key":"1605_CR45","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","volume":"373","author":"C Baigent","year":"2009","unstructured":"Baigent\u00a0C, Blackwell\u00a0L, Collins\u00a0R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849\u201360.","journal-title":"Lancet"},{"key":"1605_CR46","unstructured":"U\u2011Prevent. Homepage. 2021. www.U-Prevent.com. Accessed 23-02-2021.."},{"key":"1605_CR47","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1161\/CIRCULATIONAHA.108.814251","volume":"118","author":"PM Ridker","year":"2008","unstructured":"Ridker\u00a0PM, Paynter\u00a0NP, Rifai\u00a0N, Gaziano\u00a0JM, Cook\u00a0NR. C\u2011reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds risk score for men. Circulation. 2008;118:2243\u201351.","journal-title":"Circulation"},{"key":"1605_CR48","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ijcard.2020.09.053","volume":"325","author":"CC van\u2019t Klooster","year":"2021","unstructured":"van\u2019t Klooster\u00a0CC, Bhatt\u00a0DL, Steg\u00a0PG, et al. Predicting 10-year risk of recurrent cardiovascular events and cardiovascular interventions in patients with established cardiovascular disease: results from UCC-SMART and REACH. Int J Cardiol. 2021;325:140\u20138.","journal-title":"Int J Cardiol"},{"key":"1605_CR49","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1093\/eurheartj\/ehab210","volume":"42","author":"AD Pradhan","year":"2021","unstructured":"Pradhan\u00a0AD. Time to commence or time out for colchicine in secondary prevention of cardiovascular disease? Eur Heart\u00a0J. 2021;42:2776\u20139.","journal-title":"Eur Heart\u00a0J."},{"key":"1605_CR50","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1056\/NEJMoa2005206","volume":"383","author":"J Nordanstig","year":"2020","unstructured":"Nordanstig\u00a0J, James\u00a0S, Andersson\u00a0M, et al. Mortality with paclitaxel-coated devices in peripheral artery disease. N\u00a0Engl J Med. 2020;383:2538\u201346.","journal-title":"N Engl J Med"},{"key":"1605_CR51","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","volume":"397","author":"PM Ridker","year":"2021","unstructured":"Ridker PM, Devalaraja M, Baeres FMM, et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet. 2021;397:2060\u20139.","journal-title":"Lancet"}],"container-title":["Netherlands Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-021-01605-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12471-021-01605-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-021-01605-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,5]],"date-time":"2023-02-05T19:33:24Z","timestamp":1675625604000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12471-021-01605-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,17]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["1605"],"URL":"https:\/\/doi.org\/10.1007\/s12471-021-01605-3","relation":{},"ISSN":["1568-5888","1876-6250"],"issn-type":[{"value":"1568-5888","type":"print"},{"value":"1876-6250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,17]]},"assertion":[{"value":"7 June 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.T.L.\u00a0Fiolet, T.S.J.\u00a0Opstal, M.J.M.\u00a0Silvis, J.H.\u00a0Cornel and A.\u00a0Mosterd declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}